PAND Pandion Therapeutics 8-K2021Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
4 Jan 21
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
PAND 8-K Filings
- 4 Jan 21 Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
- 3 Dec 20 Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
- 16 Nov 20 Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
- 31 Aug 20 Pandion Reports Second Quarter 2020 Financial Results and Provides
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…